Welcome to our dedicated page for Xbiotech news (Ticker: XBIT), a resource for investors and traders seeking the latest updates and insights on Xbiotech stock.
XBiotech Inc (NASDAQ: XBIT) is a biosciences and clinical-stage biopharmaceutical company that regularly issues detailed updates on its therapeutic antibody programs, corporate actions and governance matters. Its news flow centers on the development of True Human™ antibody therapies targeting oncology, inflammatory diseases, infectious diseases, cardiovascular disease, rheumatology and stroke.
Readers of the XBiotech news page can find company announcements on key clinical trials, including randomized, double‑blind, placebo‑controlled studies for its Natrunix antibody in advanced pancreatic cancer and rheumatoid arthritis, as well as Phase I dose‑escalation work for its stroke candidate Hutrukin. The company’s releases describe study designs, endpoints, patient populations and top‑line findings, along with the company’s interpretation of safety, tolerability and outcome trends.
Beyond clinical data, XBiotech’s news also covers operational developments such as plans to expand its Austin, Texas campus with a new research and development facility to support commercialization and infectious disease programs. Corporate and capital markets updates, including a modified Dutch auction tender offer to repurchase common shares, appear alongside these scientific and operational disclosures.
Governance and leadership items, such as the appointment of lead investigators for clinical programs and the selection of medical and financial experts to the board of directors and its committees, are also reported through company news. Investors and observers who follow XBIT news can use this page to review historical announcements on pipeline progress, campus expansion, share repurchase activity and board composition, and to monitor how the company communicates developments in its True Human™ antibody platform over time.
XBiotech (NASDAQ: XBIT) announced the suspension of its rheumatology clinical program following irregularities in its Phase II study of Natrunix for Rheumatoid Arthritis. The study, which enrolled approximately 230 subjects with moderate to severe rheumatoid arthritis, failed to meet its primary endpoint of ACR20 response rate after 12 weeks. The trial evaluated Natrunix (200mg or 400mg weekly) in combination with methotrexate (MTX) against placebo with MTX.
Significant irregularities were discovered at the highest enrolling clinical sites, including multiple enrollments of the same subjects, raising concerns about data interpretation. The company has put additional planned studies in arthritis and ankylosing spondylitis on hold while evaluating these findings.
XBiotech (NASDAQ: XBIT) announced promising results from its Phase 1/2 trial for advanced pancreatic cancer treatment using Natrunix in combination with a standard chemotherapy regimen. The study, titled 1-BETTER, enrolled 65 subjects who received either the Natrunix combination or a placebo. Key findings include a 28% reduction in significant adverse events in the Natrunix group, a 33% decrease in hospitalization days, and a notable improvement in patient-reported outcomes such as reduced fatigue (22%) and pain (41%). While overall survival rates showed a trend favoring Natrunix, the small sample size led to a borderline statistical significance (p = 0.096). XBiotech emphasizes the potential of Natrunix to improve tolerability and efficacy of pancreatic cancer treatment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
XBiotech Inc. has initiated a randomized, open-label, placebo-controlled clinical study for Hutrukin, a novel therapy aimed at reducing brain injury from ischemic stroke. With over 10 million cases of ischemic strokes annually, the need for effective treatments is critical. Hutrukin seeks to mitigate reperfusion injury, a common complication following clot-removal procedures, by targeting inflammation before blood flow is restored. The Phase I study will evaluate three dosing levels for safety and pharmacokinetics, with results guiding further research phases. XBiotech leverages its proprietary True Human™ antibody technology to explore innovative treatments across various diseases.
FAQ
What is the current stock price of Xbiotech (XBIT)?
What is the market cap of Xbiotech (XBIT)?
